Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · IEX Real-Time Price · USD
25.01
-3.23 (-11.44%)
At close: Jul 26, 2024, 4:00 PM
25.49
+0.48 (1.92%)
After-hours: Jul 26, 2024, 6:43 PM EDT
Tarsus Pharmaceuticals Revenue
Tarsus Pharmaceuticals had revenue of $27.61M in the quarter ending March 31, 2024, with 1,004.56% growth. This brings the company's revenue in the last twelve months to $42.56M, up 53.22% year-over-year. In the year 2023, Tarsus Pharmaceuticals had annual revenue of $17.45M, down -32.42%.
Revenue (ttm)
$42.56M
Revenue Growth
+53.22%
P/S Ratio
22.20
Revenue / Employee
$174,430
Employees
244
Market Cap
944.92M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Avanos Medical | 680.10M |
Ironwood Pharmaceuticals | 413.55M |
Silk Road Medical | 185.49M |
BioLife Solutions | 137.30M |
Bicycle Therapeutics | 41.61M |
Tango Therapeutics | 37.23M |
Viridian Therapeutics | 288.00K |
ARS Pharmaceuticals | 10.00K |
TARS News
- 2 months ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference - GlobeNewsWire
- 2 months ago - Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements - GlobeNewsWire
- 3 months ago - Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 - GlobeNewsWire
- 3 months ago - Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon - GlobeNewsWire
- 5 months ago - Tarsus to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis - GlobeNewsWire
- 5 months ago - Tarsus Announces Pricing of $100.0 Million Public Offering - GlobeNewsWire